Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Refactor Capital
Deal Size : $4.3 million
Deal Type : Financing
Details : Parallel Bio’s platform combines immune organoids with artificial intelligence and robotics to uniquely represent organoids as a population. Organoids are 3D, self-assembling models of human biology, or so-called mini organs.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
December 20, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Refactor Capital
Deal Size : $4.3 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?